UNRESECTABLE BREAST CARCINOMA
Clinical trials for UNRESECTABLE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cocktail aims to turn tumors against themselves
Disease control OngoingThis early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat breast cancer: immune cocktails enter trial
Disease control OngoingThis phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo aims to shrink tough breast cancer tumors
Disease control OngoingThis study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…
Matched conditions: UNRESECTABLE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC